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1. Introduction {#sec005}
===============

Multiple sclerosis (MS) is a neurodegenerative and immune-mediated demyelinating disease of the human central nervous system\[[@pone.0214738.ref001]--[@pone.0214738.ref004]\]. The clinical manifestations of MS include opiate neuritis, central paralysis, sensory imbalance, balance disorder, cognitive impairment, fatigue and sleep disorders\[[@pone.0214738.ref005]\]. Women are approximately 2--3 times more likely to suffer from MS\[[@pone.0214738.ref006]\], and most patients are 20 to 50 years old. Residents of Eastern Europe are more likely to suffer from MS compared with residents of Asia, Africa and Latin America\[[@pone.0214738.ref007], [@pone.0214738.ref008]\].

Iran is muslim country in the Middle East with a latitude of 32°00 and a longitude of 53°00 and has 31 provinces. There are various ethnic groups in Iran, including Fars, Kurds, Mazani, Gilak, Lor, Turks, Arabs, and Baluch, and are now united by Iranian culture. According to the World Health Organization (WHO) in 2008, around 1.3 million people had MS worldwide, while in 2013, the prevalence of MS was 73 per 100,000 in the world and was 60 per 100,000 in Iran\[[@pone.0214738.ref009], [@pone.0214738.ref010]\]. At the moment, Iran is well known for its high prevalence of MS in the world, whereas 15 years ago, it was assumed based on the MS slope hypothesis that Iran could be a low-risk area for MS with an incidence of less than 5 per 100,000 people\[[@pone.0214738.ref011]--[@pone.0214738.ref013]\].

Despite numerous studies, the main cause of MS is still unknown. According to a hypothesis, MS carries out an autoimmune attack against self-myelin or oligodendrocytic antigens by macrophages, deadly T cells, Lymphokines, and antibodies when they enter the brain\[[@pone.0214738.ref014]\]. A combination of genetic and environmental factors such as latitude, vitamin D use, skin color, migration, meal, smoking, occupational exposure to toxins, stress, or even recent studies of specific viral infections such as Epstein-Barr virus (EBV)\[[@pone.0214738.ref015]\] and bacterial infections like mycoplasma pneumonia \[[@pone.0214738.ref016], [@pone.0214738.ref017]\] may affect this disease\[[@pone.0214738.ref006], [@pone.0214738.ref015]--[@pone.0214738.ref019]\].

Basic epidemiological information helps to quickly identify, diagnose and control the disease complications\[[@pone.0214738.ref020]\]. One of the most important goals of meta-analysis, which results from the combination of existing studies, is to increase the volume of samples and the number of studies, to reduce the difference between the available parameters and the confidence interval, which ultimately leads to solving a problem, especially in the field of medicine. In fact, such studies are a vital link between research studies and decision-making at the bedside or policies\[[@pone.0214738.ref021]--[@pone.0214738.ref023]\].

The prevalence of MS in Iran has been reported to be 5.3--89 per 100,000\[[@pone.0214738.ref002], [@pone.0214738.ref005], [@pone.0214738.ref010], [@pone.0214738.ref011], [@pone.0214738.ref013], [@pone.0214738.ref021], [@pone.0214738.ref022], [@pone.0214738.ref024]--[@pone.0214738.ref046]\]. Considering the above-mentioned issues, controversy in the prevalence of MS, the lack of global access to the precise prevalence of MS in Iran, as well as expressing the final conclusion for policy making and operational planning in Iran, this study was conducted to estimate the prevalence and incidence of MS in Iran by systematically reviewing all available documentations and their combination through meta-analysis.

2. Materials and methods {#sec006}
========================

2.1. Study protocol {#sec007}
-------------------

The present systematic review focused on MS epidemiology in Iran based on PRISMA guidelines \[[@pone.0214738.ref047]\]([S1 File](#pone.0214738.s001){ref-type="supplementary-material"}) for systematic review and meta-analysis. All the steps of research, including search, selection of studies, qualitative assessment, and data extraction were done independently by two researchers. The agreement was reached by group discussion. The protocol of this review registered at: International Prospective Register of Systematic Reviews(PROSPERO) (<https://www.crd.york.ac.uk/PROSPERO/>) Identifier: CRD42018114491 \[[@pone.0214738.ref048], [@pone.0214738.ref049]\]([S2 File](#pone.0214738.s002){ref-type="supplementary-material"}).

2.2. Search strategy {#sec008}
--------------------

The search was performed by two researchers independently. We searched the titles and abstracts of articles in six Persian databases including Scientific Information Database (SID) (<http://www.sid.ir/>), Barakat Knowledge Network System ([http://health.barakatkns.com](http://health.barakatkns.com/)), (Iranian Research Institute for Information Science and Technology (IranDoc) ([https://irandoc.ac.ir](https://irandoc.ac.ir/)), Regional Information Center for Science and Technology (RICST) (<http://en.ricest.ac.ir/>), Magiran (<http://www.magiran.com/>), Iranian National Library (<http://www.nlai.ir/>) and eight international databases including Scopus, PubMed/Medline, Science Direct, Cochrane Library, Web of Science, Embase, PsycINFO as well as Google Scholar search engine for peer-reviewed studies published without time limit until May 2018. The keywords used were \'incidence\', \'prevalence\', \'epidemiology\', \'MS\', \'multiple sclerosis\' and \'Iran\'. Boolean operators (AND & OR) were used to search by a combination of words. A sample of search strategy in PubMed database is shown in Appendix 1. The list of references of the studies was searched manually for additional reports.

2.3. Inclusion criteria (PICO) {#sec009}
------------------------------

Inclusion criteria according to **PICO** (Problem or Population, Interventions, Comparison and Outcome) \[[@pone.0214738.ref050], [@pone.0214738.ref051]\]: (1) [**P**]{.ul}opulation: all Iranian population, in all age ranges and both genders; (2) [**I**]{.ul}ntervention: diagnosis of MS by Poser or McDonald criteria for confirmed MS; (3) [**C**]{.ul}omparison: variable aimed for incidence and prevalence of MS such as gender, province, year of study and etc; (4) [**O**]{.ul}utcome: Estimate the prevalence and incidence of MS.

2.4. Exclusion criteria {#sec010}
-----------------------

The inclusion criteria were all epidemiological studies on MS. The exclusion criteria included: 1. non-random sample size; 2. sample size other than Iranian population; 3. Articles published in languages other than Persian and English; 4. Not relevant to the subject; 5. qualitative studies; case report; review articles, case reports and interventional studies, and 6. duplicate articles.

2.5. Quality assessment {#sec011}
-----------------------

Researchers assessed the quality of the selected articles using a scoring system based on the 8-item the modified Newcastle Ottawa Scale (NOS) for non-randomized studies \[[@pone.0214738.ref052]\] ([S2 File](#pone.0214738.s002){ref-type="supplementary-material"}). Each question was given a score between 0 and 1. Points 0--5, 6--7 and 8--9 were considered low quality, moderate quality and high quality, respectively. The minimum score for entering the quantitative meta-analysis process was 5 and the articles that acquired the minimum qualitative assessment score entered the process of data extraction and meta-analysis.

2.6. Screening and data extraction {#sec012}
----------------------------------

Two independent researchers (Azami M, YektaKooshali MH) screened all the articles retrieved by the search strategy based on title and abstract for eligibility according to inclusion and exclusion criteria. Any contradiction between the two researchers was discussed and finally, a consensus was reached. In addition, if necessary, the full text was examined further for more clarification at this stage. In the next step, the researchers were provided with the full text of eligible articles. Each qualified full text was reviewed independently by two researchers and a third expert (Expert-epidemiologist) was there to provide consultations on disagreements between the two researchers.

Data extraction was done by the researchers using a pre-prepared form. The data for the study included the first author, year of publication, year of study, study setting, location, sample size, geographical area, province, the prevalence of MS and MS diagnostic method, which was extracted independently by two researchers and blinded to the author\'s name, institute, and journal. If necessity, further information, and raw data were requested by contacting the author (first author, corresponding author or contacting the authors\' department) ([Table 1](#pone.0214738.t001){ref-type="table"}).

10.1371/journal.pone.0214738.t001

###### Characteristics of studies into the meta-analysis.

![](pone.0214738.t001){#pone.0214738.t001g}

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Ref.                         First author, Published Year [\*](#t001fn002){ref-type="table-fn"}   Year of Study   Study Type         Place                                  Diagnostic criteria       Sample size
  ---------------------------- -------------------------------------------------------------------- --------------- ------------------ -------------------------------------- ------------------------- -------------
  \[[@pone.0214738.ref033]\]   Etemadifar M, 2006                                                   2004--5         Cross-sectional    Isfahan                                McDonald                  3923255

  \[[@pone.0214738.ref067]\]   Sahraian MA, 2010                                                    1999--2010      Cross-sectional    Tehran                                 McDonald                  13422366

  \[[@pone.0214738.ref055]\]   Elhami SR, 2011                                                      1989--2009      Population based   Tehran                                 Poser\                    14103853
                                                                                                                                                                              (up to 2001)\             
                                                                                                                                                                              McDonald                  

  \[[@pone.0214738.ref036]\]   Heydarpour P, 2013                                                   1991--2011      Population based   Tehran                                 McDonald                  14103853

  \[[@pone.0214738.ref045]\]   Saadatnia M, 2007                                                    2003--6         Cross-sectional    Isfahan                                McDonald                  3923255

  \[[@pone.0214738.ref034]\]   Etemadifar M, 2010                                                   2003--2010      Cross-sectional    Isfahan                                McDonald                  4804458

  \[[@pone.0214738.ref059]\]   Ghandehari K, 2010                                                   2009            Population based   RazaviKhorasan                         McDonald                  5593079

  \[[@pone.0214738.ref059]\]   Ghandehari K, 2010                                                   2009            Population based   North Khorasan                         McDonald                  811572

  \[[@pone.0214738.ref059]\]   Ghandehari K, 2010                                                   2009            Population based   Southern Khorasan                      McDonald                  636420

  \[[@pone.0214738.ref002]\]   Abedini M, 2008                                                      2007            Cross-sectional    Mazandaran                             McDonald                  2893087

  \[[@pone.0214738.ref035]\]   Hashemilar M, 2011                                                   2005--9         Population based   East Azerbaijan                        McDonald                  3724620

  \[[@pone.0214738.ref040]\]   Moghtaderi A, 2012                                                   1996--2006      Cross-sectional    Sistan and Balouchestan                McDonald                  1346367

  \[[@pone.0214738.ref046]\]   Sharafaddinzadeh N, 2012                                             1997--2009      Cross-sectional    Khuzestan                              McDonald                  4200000

  \[[@pone.0214738.ref031]\]   Etemadifar M, 2013                                                   2003--2013      Population based   Isfahan                                McDonald                  4879312

  \[[@pone.0214738.ref062]\]   Kalanie H, 2003                                                      1996--2001      Cross-sectional    Tehran                                 Poser                     

  \[[@pone.0214738.ref026]\]   Jajvandian R, 2011                                                   2005--2011      Population based   North Khorasan                         \-                        867727

  \[[@pone.0214738.ref054]\]   Ebrahimi HA, 2013                                                    2013            Population based   Kerman                                 \-                        2947346

  \[[@pone.0214738.ref039]\]   Moghaddam AH, 2013                                                   2013            Population based   Kerman                                 McDonald                  207192

  \[[@pone.0214738.ref068]\]   Saman-Nezhad B,2012                                                  2012            Population based   Kermanshah                             \-                        851405

  \[[@pone.0214738.ref025]\]   Majdinasab N, 2012                                                   2005--2011      Population based   Khuzestan                              McDonald                  4531720

  \[[@pone.0214738.ref043]\]   Rezaali S, 2013                                                      2011            Population based   Qom                                    Poser (up to 2001) and\   1151672
                                                                                                                                                                              McDonald                  

  \[[@pone.0214738.ref061]\]   Izadi S, 2015                                                        2013            Population based   Fars                                   \-                        4551718

  \[[@pone.0214738.ref053]\]   Ashtari F, 2011                                                      2007            Cross-sectional    Isfahan                                                          

  \[[@pone.0214738.ref037]\]   Maghzi A, 2010                                                       2003--2007      Population based   Isfahan                                McDonald's criteria\      4559256
                                                                                                                                                                              and 2005 revisions        

  \[[@pone.0214738.ref032]\]   Etemadifar M, 2014 (Isfahan)                                         2006--2013      Population based   Isfahan                                NR                        4879312

  \[[@pone.0214738.ref032]\]   Etemadifar M, 2014 (Tehran)                                          2006--2013      Population based   Tehran                                 NR                        12183391

  \[[@pone.0214738.ref032]\]   Etemadifar M, 2014 (Fars)                                            2006--2013      Population based   Fars                                   NR                        4596658

  \[[@pone.0214738.ref032]\]   Etemadifar M, 2014 (Alborz)                                          2006--2013      Population based   Alborz                                 NR                        2412513

  \[[@pone.0214738.ref032]\]   Etemadifar M, 2014 (Markazi)                                         2006--2013      Population based   Markazi                                NR                        1413959

  \[[@pone.0214738.ref032]\]   Etemadifar M, 2014 (ChaharMahaa)                                     2006--2013      Population based   ChaharMahaal and Bakhtiari             NR                        895263

  \[[@pone.0214738.ref032]\]   Etemadifar M, 2014 (East Azerbaijan)                                 2006--2013      Population based   East Azerbaijan                        NR                        3724263

  \[[@pone.0214738.ref032]\]   Etemadifar M, 2014 (Semnan)                                          2006--2013      Population based   Semnan                                 NR                        631218

  \[[@pone.0214738.ref032]\]   Etemadifar M, 2014 (Hamadan)                                         2006--2013      Population based   Hamadan                                NR                        1758268

  \[[@pone.0214738.ref032]\]   Etemadifar M, 2014 (Qom)                                             2006--2013      Population based   Qom                                    NR                        1151672

  \[[@pone.0214738.ref032]\]   Etemadifar M, 2014 (West Azerbaijan)                                 2006--2013      Population based   West Azerbaijan                        NR                        3080576

  \[[@pone.0214738.ref032]\]   Etemadifar M, 2014(Yazd)                                             2006--2013      Population based   Yazd                                   NR                        1074428

  \[[@pone.0214738.ref032]\]   Etemadifar M, 2014(Kordestan)                                        2006--2013      Population based   Kordestan                              NR                        1493645

  \[[@pone.0214738.ref032]\]   Etemadifar M, 2014(Ardabil)                                          2006--2013      Population based   Ardabil                                NR                        1248488

  \[[@pone.0214738.ref032]\]   Etemadifar M, 2014 (Kohgiluyeh)                                      2006--2013      Population based   Kohgiluyeh and Boyer-Ahmad             NR                        658621

  \[[@pone.0214738.ref032]\]   Etemadifar M, 2014 (Mazandaran)                                      2006--2013      Population based   Mazandaran                             NR                        3073943

  \[[@pone.0214738.ref032]\]   Etemadifar M, 2014 (Guilan)                                          2006--2013      Population based   Guilan                                 NR                        2480874

  \[[@pone.0214738.ref032]\]   Etemadifar M, 2014 (Kerman)                                          2006--2013      Population based   Kerman                                 NR                        2938988

  \[[@pone.0214738.ref032]\]   Etemadifar M, 2014 (Khorasan-Razavi)                                 2006--2013      Population based   Razavi Khorasan                        NR                        5994402

  \[[@pone.0214738.ref032]\]   Etemadifar M, 2014 (Bushehr)                                         2006--2013      Population based   Bushehr                                NR                        103949

  \[[@pone.0214738.ref032]\]   Etemadifar M, 2014 (Ilam)                                            2006--2013      Population based   Ilam                                   NR                        557599

  \[[@pone.0214738.ref032]\]   Etemadifar M, 2014 (Khuzestan)                                       2006--2013      Population based   Khuzestan                              NR                        4531720

  \[[@pone.0214738.ref032]\]   Etemadifar M, 2014 (Golestan)                                        2006--2013      Population based   Golestan                               NR                        1777014

  \[[@pone.0214738.ref032]\]   Etemadifar M, 2014 (Lorestan)                                        2006--2013      Population based   Lorestan                               NR                        1754244

  \[[@pone.0214738.ref032]\]   Etemadifar M, 2014 (Zanjan)                                          2006--2013      Population based   Zanjan                                 NR                        1015734

  \[[@pone.0214738.ref032]\]   Etemadifar M, 2014(Kermanshah)                                       2006--2013      Population based   Kermanshah                             NR                        1945227

  \[[@pone.0214738.ref032]\]   Etemadifar M, 2014 (Hormozgan)                                       2006--2013      Population based   Hormozgan                              NR                        1578183

  \[[@pone.0214738.ref032]\]   Etemadifar M, 2014 (North Khorasan)                                  2006--2013      Population based   North Khorasan                         NR                        867727

  \[[@pone.0214738.ref032]\]   Etemadifar M, 2014 (South Khorasan)                                  2006--2013      Population based   South Khorasan                         NR                        662534

  \[[@pone.0214738.ref032]\]   Etemadifar M, 2014(Qazvin)                                           2006--2013      Population based   Qazvin                                 NR                        1201565

  \[[@pone.0214738.ref032]\]   Etemadifar M, 2014 (Sistan and Baluchestan)                          2006--2013      Population based   Sistan and Baluchestan                 NR                        2534327

  \[[@pone.0214738.ref044]\]   Saadat SMS, 2013                                                     2010            Cross-sectional    Guilan                                 McDonald                  2480874

  \[[@pone.0214738.ref042]\]   Raiesi R, 2014                                                       1991--2011      Population based   Kohgiluyeh and Boyer-Ahmad             McDonald                  895263

  \[[@pone.0214738.ref060]\]   Izadi S, 2015                                                        2011            Population based   Fars                                   NR                        4596658

  \[[@pone.0214738.ref005]\]   Nedjat S, 2006                                                       2006            Population based   Tehran                                 NR                        7803883

  \[[@pone.0214738.ref071]\]   Yousefi B, 2017                                                      2005--2009      Population based   East Azerbaijan                        McDonald                  3724620

  \[[@pone.0214738.ref071]\]   Yousefi B, 2017                                                      2010--2014      Population based   East Azerbaijan                        McDonald                  3909652

  \[[@pone.0214738.ref064]\]   Mazdeh M, 2016                                                       2015--2018      Population based   Hamadan                                McDonald                  

  \[[@pone.0214738.ref070]\]   Tolou-Ghamari Z, 2015                                                2010--2014      Population based   Isfahan                                McDonald                  4879312

  \[[@pone.0214738.ref069]\]   Shahbeigi S, 2012                                                    2010--2014      Population based   12 different major provinces of Iran   McDonald                  46695319

  \[[@pone.0214738.ref063]\]   Khamarnia M, 2016                                                    2010            Population based   Fars                                   McDonald                  4596658

  \[[@pone.0214738.ref063]\]   Khamarnia M, 2016                                                    2011            Population based   Fars                                   McDonald                  4596658

  \[[@pone.0214738.ref063]\]   Khamarnia M, 2016                                                    2012            Population based   Fars                                   McDonald                  4596658

  \[[@pone.0214738.ref013]\]   Dehghani R, 2015                                                     2006            Population based   All Iran                               McDonald                  70495782

  \[[@pone.0214738.ref013]\]   Dehghani R, 2015                                                     2011            Population based   All Iran                               McDonald                  75149669

  \[[@pone.0214738.ref057]\]   Eskandarieh Sh, 2017                                                 2013            Population based   Tehran                                 McDonald                  12559000

  \[[@pone.0214738.ref057]\]   Eskandarieh Sh, 2017                                                 2014            Population based   Tehran                                 McDonald                  12559000

  \[[@pone.0214738.ref057]\]   Eskandarieh Sh, 2017                                                 2014            Population based   Tehran                                 McDonald                  12559000

  \[[@pone.0214738.ref066]\]   Sabbagh S, 2017                                                      2015--2018      Population based   Khuzestan                              McDonald                  957133

  \[[@pone.0214738.ref065]\]   Mousavizadeh A, 2017                                                 2015--2018      Population based   Kohgiluyeh and Boyer-Ahmad             McDonald                  713052

  \[[@pone.0214738.ref056]\]   Eskandarieh Sh, 2017                                                 2015            Population based   Tehran                                 McDonald                  13267637

  \[[@pone.0214738.ref058]\]   Eskandarieh Sh, 2018                                                 2017            Population based   Tehran                                 McDonald                  13441124
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**NR:** Not reported

\* Repetitive studies have been included and estimated the prevalence and incidence for more than 1 year and also regions. Each data was considered separately because of assessing the slope of prevalence and incidence in the years and estimating which region is the highest or lowest.

2.7. Data analysis {#sec013}
------------------

To evaluate the heterogeneity of the studies, Cochran\'s Q and I^2^ tests were used. Heterogeneity was defined as I^2^\> 50% and the Cochran\'s Q test was defined as \< 0.05. Therefore, the random effects model was used to estimate the prevalence and incidence of MS with high heterogeneity. To estimate the effect of gender, we used the total number and the number of events (MS) in men and women groups and we calculated the odds ratio (OR) and 95% CI. In this study, a sensitivity analysis was also performed to verify the stability of the data. In order to find the source of heterogeneity, a subgroup analysis was conducted in terms of geographic area, year of study, province, and study setting while a meta-regression model was used for the prevalence and incidence of MS in terms of year of studies. Begg and Egger's tests were used to assess publication bias. Data were analyzed using Comprehensive meta-analysis ver. 2 software. P\<0.05 was considered significant.

3. Results {#sec014}
==========

3.1. Study characteristics and methodological quality {#sec015}
-----------------------------------------------------

Of 392 studies found in the initial search using the search strategy, 138 potentially relevant studies were found to be eligible for retrieval and evaluation. By examining the full text of the studies, 65 studies were excluded due to non-MS or non-Iranian patients (27), non-randomized (18) and inadequate data according to the data extraction checklist (14), articles to the editor without original data, review and case report (5) and low quality (1). Finally, 39 articles (included 103 studies for prevalence and 34 studies for incidence) entered the meta-analysis process after qualitative assessment. The flow diagram of the identification and selection of studies is illustrated in ([Fig 1](#pone.0214738.g001){ref-type="fig"}) and the characteristics of studies are shown in ([Table 1](#pone.0214738.t001){ref-type="table"}) \[[@pone.0214738.ref002], [@pone.0214738.ref005], [@pone.0214738.ref013], [@pone.0214738.ref025], [@pone.0214738.ref026], [@pone.0214738.ref031]--[@pone.0214738.ref037], [@pone.0214738.ref039], [@pone.0214738.ref040], [@pone.0214738.ref042]--[@pone.0214738.ref046], [@pone.0214738.ref053]--[@pone.0214738.ref071]\].

![Study flow diagram.](pone.0214738.g001){#pone.0214738.g001}

3.2. Pooled prevalence of MS and sensitivity analysis {#sec016}
-----------------------------------------------------

The total heterogeneity was high (I^2^ = 99.92% and P\< 0.001). The prevalence of MS in Iran was estimated to be 29.3/ 100,000 (95% CI: 25.6--33.5) based on random effects model ([Fig 2](#pone.0214738.g002){ref-type="fig"}). The lowest and highest prevalence was found in studies in Southern Khorasan in 2009 (5.3/ 100,000) and Isfahan in 2013 (89/ 100,000), respectively (Figs [2](#pone.0214738.g002){ref-type="fig"} and [3](#pone.0214738.g003){ref-type="fig"}). The sensitivity analysis of the prevalence of MS and its 95% CI was estimated irrespective of one study at a time, and the results showed that the pooled estimate was robust ([S1 Fig](#pone.0214738.s004){ref-type="supplementary-material"}).

![The prevalence of multiple sclerosis in Iran.\
Random effect model.](pone.0214738.g002){#pone.0214738.g002}

![Distribution of MS in Iran based on geographical classification.\
High risk 30/100,000 intermediate risk 5-30/100,000 and low risk 5/100,000 (as Wade scaled prevalence of MS globally \[[@pone.0214738.ref072]\]).](pone.0214738.g003){#pone.0214738.g003}

3.3. Subgroup analysis of MS prevalence based on region, province, study design, and year of study {#sec017}
--------------------------------------------------------------------------------------------------

The Subgroup analysis of MS prevalence in Iran is shown in ([Table 2](#pone.0214738.t002){ref-type="table"}) and ([S1](#pone.0214738.s004){ref-type="supplementary-material"}--[S6](#pone.0214738.s009){ref-type="supplementary-material"} Figs). Significant difference was observed in the prevalence of MS in the geographical regions (P\< 0.001) ([S2 Fig](#pone.0214738.s005){ref-type="supplementary-material"}), province (P\< 0.001) ([S3 Fig](#pone.0214738.s006){ref-type="supplementary-material"}), study design (P = 0.015) ([S4 Fig](#pone.0214738.s007){ref-type="supplementary-material"}), and year of study (P\< 0.001) ([S5 Fig](#pone.0214738.s008){ref-type="supplementary-material"}).

10.1371/journal.pone.0214738.t002

###### MS prevalence based on region, gender, provinces, year of study and design.

![](pone.0214738.t002){#pone.0214738.t002g}

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                                                             Studies (N)[\*](#t002fn002){ref-type="table-fn"}   Sample (N)   Heterogeneity   95% CI      Pooled\                                   
                                                                                                                                                                   (Per 100,000)                             
  -------------------------------------------------------------------- -------------------------------------------------- ------------ --------------- ----------- --------------- ------------ ------------ ------
  Region                                                               12 different                                       1            19524           46695319    \-              \-           41.2--42.4   42.4

  All Iran                                                             2                                                  51962        145645451       99.97       \< 0.001        20.4--57.4   34.2         

  Center                                                               47                                                 174229       368149059       99.94       \< 0.001        28.6--43.1   35.1         

  East                                                                 8                                                  3756         24011421        99.62       \< 0.001        5.3--18.1    9.8          

  North                                                                14                                                 11640        32250226        99.50       \< 0.001        18.7--32.0   24.5         

  South                                                                13                                                 17466        40504544        99.69       \< 0.001        25.6--44.6   33.8         

  West                                                                 7                                                  4237         12534786        98.01       \< 0.001        22.4--41.9   30.6         

  Test for subgroup differences: Q = 45.66, df(Q) = 6, P\< 0.001                                                                                                                                             

  Gender                                                               Male                                               31           25711           76907082    94.77           \<0.0001     13.3--20.5   16.5

  Female                                                               31                                                 74356        75432131        99.87       \< 0.001        36.2--55.4   44.8         

  Rate ratio of female to male: OR = 3.01 (2.79--2 = 3.24, P\<0.001)                                                                                                                                         

  Province                                                             12 different major provinces of Iran               1            19524           46695319    \-              \-           41.2--42.4   41.8

  Alborz                                                               1                                                  1737         2412513         \-          \-              68.7--75.5   72.0         

  All Iran                                                             2                                                  51962        145645451       99.97       \< 0.001        20.4--57.4   34.2         

  Ardabil                                                              1                                                  506          1248488         \-          \-              37.1--44.2   40.5         

  Bushehr                                                              1                                                  33           103949          \-          \-              22.6--44.7   31.7         

  Chahar Mahaal and Bakhtiari                                          1                                                  537          895263          \-          \-              55.1--65.3   60.0         

  East Azerbaijan                                                      4                                                  6971         1508315         99.74       \< 0.001        25.8--67.4   41.7         

  Fars                                                                 4                                                  11867        18441692        99.12       \< 0.001        52.3--76.9   63.4         

  Golestan                                                             1                                                  373          1777014         \-          \-              19.0--23.2   21.0         

  Guilan                                                               2                                                  1643         4961748         97.19       \< 0.001        24.5--43.9   32.8         

  Hamadan                                                              1                                                  985          1758268         \-          \-              52.6--59.6   56.0         

  Hormozgan                                                            1                                                  300          1578183         \-          \-              17.0--21.3   19.0         

  Ilam                                                                 1                                                  162          557599          \-          \-              24.9--33.9   29.1         

  Isfahan                                                              7                                                  21302        32559015        99.79       \< 0.001        43.5--79.3   58.7         

  Kerman                                                               3                                                  2102         6085168         85.39       \< 0.001        31.0--40.4   35.4         

  Kermanshah                                                           2                                                  818          3890454         86.51       \< 0.001        17.4--25.3   21.0         

  Khuzestan                                                            4                                                  3164         14295552        98.11       \< 0.001        15.3--26.2   20.1         

  Kohgiluyeh and Boyer-Ahmad                                           4                                                  1163         2030302         96.72       \< 0.001        40.3--76.8   55.7         

  Kordestan                                                            1                                                  612          1493645         \-          \-              37.9--44.4   41.0         

  Lorestan                                                             1                                                  351          1754244         \-          \-              18.0--22.2   20.0         

  Markazi                                                              1                                                  862          1413959         \-          \-              57.0--65.2   61.0         

  Mazandaran                                                           2                                                  1781         5996375         99.43       \< 0.001        14.4--53.9   27.9         

  North Khorasan                                                       3                                                  332          2547026         92.70       \< 0.001        8.3--18.8    12.5         

  Qazvin                                                               1                                                  192          1201565         \-          \-              13.9--18.4   16.0         

  Qom                                                                  2                                                  1180         2303344         0           0.60            48.8--54.2   51.2         

  Razavi Khorasan                                                      2                                                  2879         11587481        99.82       \< 0.001        7.9--59.0    21.6         

  Semnan                                                               1                                                  353          631218          \-          \-              50.4--62.1   55.9         

  Sistan and Balouchestan                                              5                                                  771          11761406        75.34       \< 0.001        5.6--7.5     6.5          

  South Khorasan                                                       2                                                  140          1298954         99.77       \< 0.001        3.2--27.3    9.3          

  Tehran                                                               28                                                 146270       322611718       99.96       \< 0.001        20.7--36.7   27.6         

  West Azerbaijan                                                      1                                                  1309         3080576         \-          \-              20.7--36.7   27.6         

  Yazd                                                                 1                                                  440          1074428         \-          \-              37.3--45.0   41.0         

  Zanjan                                                               1                                                  193          1015734         \-          \-              16.5--21.9   19.0         

  Test for subgroup differences: Q = 2559.92, df(Q) = 32, P\< 0.001                                                                                                                                          

  Year of study                                                        \< 1990                                            2            1110            17539552    69.13           0.072        5.7--7.0     6.3

  1990--1994                                                           5                                                  4382         47222144        97.14       \< 0.001        7.6--10.8    9.1          

  1995--1999                                                           5                                                  9763         53251981        98.62       \< 0.001        15.1--21.3   17.9         

  2000--2004                                                           5                                                  20412        60955029        99.27       \< 0.001        27.9--38.6   32.8         

  2005--2009                                                           20                                                 58545        182277428       99.82       \< 0.001        15.5--23.6   19.1         

  2010--2014                                                           51                                                 151690       280165726       99.81       \< 0.001        35.8--45.8   40.5         

  2015--2018                                                           4                                                  36912        28378946        99.76       \< 0.001        50.7--85.0   65.6         

  Test for subgroup differences: Q = 744.07, df(Q) = 6, P\< 0.001                                                                                                                                            

  Study design                                                         Population based                                   82           266175          627821102   99.83           \< 0.001     27.0--35.9   31.1

  Cross-sectional                                                      10                                                 16639        41969704        99.92       \< 0.001        11.7--27.3   17.9         

  Test for subgroup differences: Q = 5.89, df(Q) = 1, P = 0.015                                                                                                                                              
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

N: Number; CI: confidence interval

\* Some studies have been included and estimated the prevalence and incidence for more than 1 year and also regions. Each data was considered separately because of assessing the slope of prevalence and incidence in the years and estimating which region is the highest or lowest.

3.4. Prevalence of MS based on gender {#sec018}
-------------------------------------

The prevalence of MS in men and women was estimated to be 16.5/ 100,000 (95% CI: 13.7--23.4) and 44.8/ 100,000 (95% CI: 36.3--61.6), respectively ([Fig 4](#pone.0214738.g004){ref-type="fig"}). The OR female/ male of MS prevalence was estimated to be 3.01 (95% CI: 2.79--3.24, P\< 0.001) ([Table 2](#pone.0214738.t002){ref-type="table"}) ([S6 Fig](#pone.0214738.s009){ref-type="supplementary-material"}).

![The prevalence of multiple sclerosis in men (A) and women (B). Random effect model.](pone.0214738.g004){#pone.0214738.g004}

3.5. Pooled incidence of MS and sensitivity analysis {#sec019}
----------------------------------------------------

The total heterogeneity was high (I^2^ = 99.96% and P\< 0.001). The incidence of MS in Iran was estimated according to 34 studies to be 3.4/ 100,000 (95% CI: 1.8--6.2) based on random effects model ([Fig 5](#pone.0214738.g005){ref-type="fig"}). The sensitivity analysis results are shown in ([S7 Fig](#pone.0214738.s010){ref-type="supplementary-material"}).

![The incidence of multiple sclerosis in Iran.\
Random effect model.](pone.0214738.g005){#pone.0214738.g005}

3.6. Subgroup analysis of MS incidence based on region, province, study design, and year of study {#sec020}
-------------------------------------------------------------------------------------------------

The Subgroup analysis of MS incidence in Iran is shown in ([Table 3](#pone.0214738.t003){ref-type="table"}). Significant difference was observed in the prevalence of MS in the geographical regions (P \< 0.001) ([S8 Fig](#pone.0214738.s011){ref-type="supplementary-material"}), province (P\< 0.001) ([S9 Fig](#pone.0214738.s012){ref-type="supplementary-material"}) and year of study (P\< 0.001) ([S10 Fig](#pone.0214738.s013){ref-type="supplementary-material"}), but study design was no significant difference (P = 0.123) ([S11 Fig](#pone.0214738.s014){ref-type="supplementary-material"}).

10.1371/journal.pone.0214738.t003

###### MS incidence based on region, gender, provinces, year of study and design.

![](pone.0214738.t003){#pone.0214738.t003g}

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                                                            Studies (N)[\*](#t003fn002){ref-type="table-fn"}   Sample (N)   Heterogeneity   95% CI      Pooled\                                   
                                                                                                                                                                  (Per 100,000)                             
  ------------------------------------------------------------------- -------------------------------------------------- ------------ --------------- ----------- --------------- -------------- ---------- -----
  Region                                                              Center                                             26           41134           284522333   99.97           \< 0.001       2.0--7.6   3.9

  East                                                                4                                                  94           9227079         67.80       0.025           0.7--1.4       1.0        

  South                                                               4                                                  1002         17860233        98.43       \< 0.001        2.9--8.2       4.9        

  Test for subgroup differences: Q = 28.94, df(Q) = 2, P\< 0.001                                                                                                                                            

  Gender                                                              Male                                               31           2158            136555427   99.87           \< 0.001       1.0--1.4   1.2

  Female                                                              31                                                 76156        75432131        99.87       \< 0.001        39.3--59.1     48.2       

  Rate ratio of female to male: OR = 3.04 (2.85--3.24, P\< 0.001)                                                                                                                                           

  Province                                                            Fars                                               3            908             13585254    97.40           \< 0.001       4.2--9.6   6.3

  Isfahan                                                             2                                                  574          8802567         98.81       \< 0.001        2.4--13.5      5.7        

  Khuzestan                                                           1                                                  94           4274979         \-          \-              1.8--2.7       2.2        

  Sistan and Balouchestan                                             4                                                  94           9227079         67.80       0.025           0.7--1.4       1.0        

  Tehran                                                              24                                                 40560        275719766       99.97       \< 0.001        1.8--7.6       3.7        

  Test for subgroup differences: Q = 49.07, df(Q) = 4, P\< 0.001                                                                                                                                            

  Year of study                                                       \< 1990                                            1            60              8769776     \-              \-             0.5--0.9   0.7

  1990--1994                                                          5                                                  586          47222144        93.90       \< 0.001        0.8--1.6       1.2        

  1995--1999                                                          5                                                  1402         53251981        79.37       \< 0.001        2.3--2.9       2.6        

  2000--2004                                                          6                                                  2919         65291907        90.76       \< 0.001        3.9--5.0       4.4        

  2005--2009                                                          11                                                 3474         76707337        98.09       \< 0.001        2.2--3.7       2.8        

  2010--2014                                                          5                                                  13887        46925376        99.96       \< 0.001        2.0--56.7      10.6       

  2015--2018                                                          1                                                  19902        13441124        \-          \-              146.0--150.1   148.1      

  Test for subgroup differences: Q = 10943.73, df(Q) = 6, P\< 0.001                                                                                                                                         

  Study design                                                        Population based                                   27           41468           289305020   98.66           \< 0.001       2.0--7.7   4.0

  Cross-sectional                                                     7                                                  762          22304625        99.97       \< 0.001        0.9--3.8       1.8        

  Test for subgroup differences: Q = 2.38, df(Q) = 1, P = 0.123                                                                                                                                             
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

N: Number; CI: confidence interval

\* Some studies have been included and estimated the prevalence for more than 1 year and also regions. Each data was considered separately because of assessing the slope of prevalence in the years and estimating which region is the highest or lowest.

3.7. Incidence of MS based on gender {#sec021}
------------------------------------

The incidence of MS in men was estimated to be 16.5/ 100,000 (95% CI: 13.7--23.4) and the incidence of MS in women was 44.8/ 100,000 (95% CI: 36.3--61.6) ([Fig 6](#pone.0214738.g006){ref-type="fig"}). The OR female/male of MS incidence was estimated to be 3.04 (2.85--3.24, P\< 0.001) ([Table 2](#pone.0214738.t002){ref-type="table"}) ([S12 Fig](#pone.0214738.s015){ref-type="supplementary-material"}).

![The incidence of multiple sclerosis in men (A) and women (B). Random effect model.](pone.0214738.g006){#pone.0214738.g006}

3.8. Meta-regression {#sec022}
--------------------

The meta-regression model for prevalence and incidence of MS was significantly higher in terms of year of study \[(meta-regression coefficient: 0.065, 95% CI 0.053 to 0.077, P\< 0.001) for prevalence of MS and (meta-regression coefficient: 0.100, 95% CI 0.063 to 0.136, P\< 0.001) for incidence of MS\] ([Fig 7](#pone.0214738.g007){ref-type="fig"}). Moreover, the meta-regression model for prevalence and incidence of MS based on the year was also studied in men \[(meta-regression coefficient: 0.202, 95% CI 0.157 to 0.248, P\< 0.001) for prevalence of MS and (meta-regression coefficient: 0.065, 95% CI 0.046 to 0.0840, P\< 0.001) for incidence of MS\] and women \[(meta-regression coefficient: 0.216, 95% CI 0.169 to 0.264, P\< 0.001) for prevalence of MS and (meta-regression coefficient: 0.219, 95% CI 0.176 to 0.263, P\< 0.001) for incidence of MS\] and it was increasing significantly ([S13](#pone.0214738.s016){ref-type="supplementary-material"} and [S14](#pone.0214738.s017){ref-type="supplementary-material"} Figs).

![Meta-regression of MS in Iran according to year of studies.\
Prevalence (A) and incidence (B).](pone.0214738.g007){#pone.0214738.g007}

3.9. Publication bias {#sec023}
---------------------

Publication bias in the studies of incidence (Egger\< 0.001, and Begg's\< 0.001) and prevalence (Egger\< 0.001, and Begg's = 0.045) of MS was significant ([S15 Fig](#pone.0214738.s018){ref-type="supplementary-material"}).

4. Discussion {#sec024}
=============

The present study is the first systematic review and meta-analysis on the epidemiology of MS in Iran. According to the results of the present meta-analysis, the prevalence and incidence of MS in Iran is estimated to be 29.3/ 100,000 and 3.4/ 100,000, which is more than some Middle Eastern countries (Oman, Libya, Lebanon, Iraq, Kuwait, and Tunisia)\[[@pone.0214738.ref073]--[@pone.0214738.ref078]\] and less than some other countries (UAE, city of Amman in Jordan and Saudi Arabia) \[[@pone.0214738.ref079]--[@pone.0214738.ref081]\]. However, it should be noted that most studies in our meta-analysis process were based on data from MS centers, and the lack of recording the information of some people with MS was due to non-compulsory membership in this center and the real prevalence of MS is expected to be greater than this figure. In 2016, Nasr et al. \[[@pone.0214738.ref041]\] investigated the prevalence of MS among Iranian migrants. The prevalence of MS among Iranian migrants was 21/ 100,000 in Mumbai (India) in 1985 and 433/ 100,000 in British Columbia (Canada) in 2012. In five different studies, the MS prevalence in the studied areas was reported from 1.33 in Mumbai (India) to 240 in British Columbia (Canada)\[[@pone.0214738.ref082]--[@pone.0214738.ref086]\]. The acculturative stress in migrants may help to relate the onset of illness and migration. The acculturative stress is the tension or pressure associated with the experience of a second culture that may have adverse effects on physical or mental health \[[@pone.0214738.ref087]\] and shows that stress and anxiety have a potential role in MS development\[[@pone.0214738.ref088]\]. Nish et al. recently showed in a study that acculturative stress is related to higher inflammatory markers in a Chinese migrant population\[[@pone.0214738.ref089]\].

In the past, the behavior and distribution of MS disease were associated with latitude and was reported to be lower in areas with a higher latitude. Overall, according to a report by WHO in 2008, the highest reported MS prevalence was in North America and Europe, and the lowest reported MS prevalence was in countries near the equator. However, this pattern is changing and areas with lower prevalence are changing to areas with higher prevalence\[[@pone.0214738.ref010], [@pone.0214738.ref015], [@pone.0214738.ref018], [@pone.0214738.ref090]\]. In the present study, there was a significant difference between the five geographical regions of Iran in terms of the prevalence and incidence of MS based on the results of the initial studies.

Based on the present meta-analysis, the OR of prevalence and incidence of MS in women was 2.52 and 3.04, respectively compared with men, which was a significant relationship (P\< 0.001). This result is similar to the results in previous studies \[[@pone.0214738.ref021], [@pone.0214738.ref038], [@pone.0214738.ref055], [@pone.0214738.ref091]--[@pone.0214738.ref093]\].

According to the meta-regression model, the prevalence and incidence of MS in Iran increased significantly (p\< 0.001) with an increase in year of studies\[[@pone.0214738.ref021], [@pone.0214738.ref038], [@pone.0214738.ref091]--[@pone.0214738.ref093]\].

Various factors such as the lack of prevention and screening programs can be important factors in increasing the prevalence of the disease. In addition to changes in the pattern of food consumption, food quality has also changed a lot recently \[[@pone.0214738.ref010], [@pone.0214738.ref013], [@pone.0214738.ref030]\]. According to the WHO, the use of tobacco, fat, salt and sugar higher than the limit in foods that cause overweight and obesity, industrialization, urbanization and economic development can play a significant role in the development of chronic diseases\[[@pone.0214738.ref094]\]. In a study in the United States on 8983 MS patients, it was found that 25% of patients were obese and 31.3% were overweight. In addition, 18.2% were at risk of alcohol misuse by themselves or their relatives\[[@pone.0214738.ref095]\].

Since there are no particular laws and regulations on the purchase and use of chemicals in Iran, they are easily accessible to people and this may increase the risk of diseases such as MS, which is caused by exposure to chemicals. Although in some studies, contact with industrial solvents has been identified as a risk factor for MS, it has not yet been confirmed for sure\[[@pone.0214738.ref096]--[@pone.0214738.ref098]\].

The existence of particles such as PM10 in the air of Iranian cities\[[@pone.0214738.ref010], [@pone.0214738.ref028], [@pone.0214738.ref030], [@pone.0214738.ref099]--[@pone.0214738.ref102]\], natural radiation of radon from soil (Ramsar, Iran) \[[@pone.0214738.ref103]\] and unsupervised use of decorative stones and granite in Iran\[[@pone.0214738.ref027], [@pone.0214738.ref104]\] may increase the risk of MS. However, few studies have been conducted regarding the relationship between the above parameters and MS.

According to the Ministry of Health in Iran, the rate of smoking has risen to about 60 billion cigarettes per year\[[@pone.0214738.ref029], [@pone.0214738.ref105]\]. Inhaling cigarette smoke exacerbates the effect on chronic diseases \[[@pone.0214738.ref106], [@pone.0214738.ref107]\]. According to an ecological study by Dehghani et al. in Iran, the prevalence of illness is higher in provinces where cigarette smoking is higher among males\[[@pone.0214738.ref013]\]. Since cigarette smoking increases the frequency and duration of respiratory infections and it causes MS relapse\[[@pone.0214738.ref037]\], the risk of cigarette smoking for MS with an OR of 1.55, 95% CI \[1.48--1.62\], P\<0.001 was confirmed in the recent meta-analysis.

According to the WHO, the prevalence of MS is higher in countries with higher income levels. However, the diseases may progress more in less developed countries due to less access to diagnostic facilities, although the disparity is so high that scarce diagnostic facilities cannot be considered as the main factor\[[@pone.0214738.ref108]\].

Studies have shown that vitamin D deficiency is inversely related to the risk of MS \[[@pone.0214738.ref109], [@pone.0214738.ref110]\] and its deficiency is an epidemic, which affects 20--25% of the population in Asia, America, Canada, Europe and Australia\[[@pone.0214738.ref111]\]. This is becoming acuter in the Middle East because of changes in lifestyle conditions and less sunlight\[[@pone.0214738.ref112]\]. Systematic reviews and meta-analyses in Iran have reported a high prevalence of vitamin D deficiency\[[@pone.0214738.ref091], [@pone.0214738.ref092]\].

The period of MS is often unpredictable, but some factors can predict a patient\'s prognosis. The indicators of a good prognosis can be female gender, those with a history of disease before the age of 35, those who were only attacked in one area of the brain, those who had no brain stem involvement and patients who had recovered after the attacks\[[@pone.0214738.ref010]\]. To achieve successful symptom control, multiple controls are needed to prevent or stop the symptoms. Effective communication, training, exercise, professional support, and pharmacological interventions are vital for effective control of multiple sclerosis symptoms.

5. Limitations {#sec025}
==============

1\. The insensitivity of internal databases to operators "AND" and "OR" to search for the combination. 2. Since Tehran is the main medical center of many cities and provinces, patients in the studies in Tehran, are not just from Tehran.

3\. No separation of rural and urban prevalence of MS

6. Conclusion {#sec026}
=============

The present meta-analysis showed that the prevalence and incidence of MS in Iran is high (as Wade scaled prevalence of MS globally\[[@pone.0214738.ref072]\]) and is rising over time. The results of this study provide useful information for neurologists and health policy makers and can provide a general overview of MS epidemiology in Iran.

Appendix 1: PubMed search strategy {#sec027}
==================================

1.  Exp. \'Epidemiology\'

2.  Exp.\'Prevalence\'

3.  Exp.\'Incidence'\'

4.  Exp.MS\'

5.  Exp.\'Multiple Sclerosis \'

6.  Exp.\'Iran\'

7.  1 OR 2 OR 3

8.  4 OR 5

9.  7 AND 8 AND 9

Supporting information {#sec028}
======================

###### PRISMA checklist.

(DOC)

###### 

Click here for additional data file.

###### The review protocol which has been registered in PROSPERO International Prospective Register of Systematic Reviews.

(PDF)

###### 

Click here for additional data file.

###### Newcastle-Ottawa scale checklist.

(PDF)

###### 

Click here for additional data file.

###### Sensitivity analysis for prevalence of multiple sclerosis in Iran.

(TIF)

###### 

Click here for additional data file.

###### Subgroup analysis for multiple sclerosis prevalence based on region.

(TIF)

###### 

Click here for additional data file.

###### Subgroup analysis for multiple sclerosis prevalence based on province.

(TIF)

###### 

Click here for additional data file.

###### Subgroup analysis for multiple sclerosis prevalence based on study design.

(TIF)

###### 

Click here for additional data file.

###### Subgroup analysis for multiple sclerosis prevalence based on study year.

(TIF)

###### 

Click here for additional data file.

###### 

The OR female to male of MS prevalence (A) and incidence (B).

(TIF)

###### 

Click here for additional data file.

###### Sensitivity analysis for prevalence of multiple sclerosis in Iran.

(TIF)

###### 

Click here for additional data file.

###### Subgroup analysis for multiple sclerosis incidence based on region.

(TIF)

###### 

Click here for additional data file.

###### Subgroup analysis for multiple sclerosis incidence based on province.

(TIF)

###### 

Click here for additional data file.

###### Subgroup analysis for multiple sclerosis incidence based on study year.

(TIF)

###### 

Click here for additional data file.

###### Subgroup analysis for multiple sclerosis incidence based on study design.

(TIF)

###### 

Click here for additional data file.

###### The OR female/male of MS incidence.

(TIF)

###### 

Click here for additional data file.

###### 

Prevalence of Multiple Sclerosis in Iran in terms of men (A) and women (B).

(TIF)

###### 

Click here for additional data file.

###### 

Incidence of Multiple Sclerosis in Iran in terms of men (A) and women (B).

(TIF)

###### 

Click here for additional data file.

###### 

Publication bias for prevalence studies (A) and update (B) multiple sclerosis in Iran.

(TIF)

###### 

Click here for additional data file.
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